CareDx announced a definitive agreement to sell its lab products business to EuroBio Scientific for $170 million in cash. Under the deal, CareDx will provide transition services for at least six months, while EuroBio will receive exclusive, perpetual rights to distribute post-transplant monitoring tests in North America. The package includes AlloSeq cfDNA and an IVD kit version of CareDx’s AlloSure dd-cfDNA lab-developed test. CareDx said it plans to use proceeds to invest in precision diagnostics and potentially return capital to shareholders. The transaction is expected to close by the end of the third quarter, subject to Swedish regulatory review, and reinforces consolidation pressure within transplant diagnostics product lines.